62 completed, 21 terminated, 17 recruiting, 13 unknown. 130 Phase 2, 40 Phase 1, 12 Phase 3.
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC) KM-023 - Pachyonychia Congenita | Phase 2 | Not yet recruiting | Orvida Pharma (formerly Kamari Pharma) | 10 | 2026-12-01 | 2026-10-26 |
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex Filsuvez - Epidermolysis Bullosa Simplex | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-10-01 | 2026-08-10 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-11-02 |
| GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) - RDEB, Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 9 | 2026-01-07 | 2026-03-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex 5% TolaSure Topical Gel, Topical Placebo Gel - Epidermolysis Bullosa Simplex | Phase 2 | Recruiting | BioMendics, LLC | 40 | 2025-09-11 | 2026-08-13 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
| Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases Subtenon Injection of Autologous Platelet-Rich Plasma - Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Active not recruiting | Rubens Camargo Siqueira | 30 | 2025-01-04 | 2026-07-01 |
| A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT Hemopfin+Green Light, Vehicle+Green Light - Port-wine Birthmarks, Port-Wine Stain | Phase 2 | Recruiting | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 84 | 2024-09-21 | 2026-03-03 |
| Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Gentamicin Injectable Solution - Ichthyosis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 26 | 2024-09-01 | 2024-09-05 |
| MSC EVs in Dystrophic Epidermolysis Bullosa AGLE-102 - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | Aegle Therapeutics | 8 | 2024-08-13 | 2025-06-25 |
| A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized Apremilast treatment - Epidermolysis Bullosa Simplex, Genodermatosis | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2024-08-06 | 2025-02-24 |
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
Showing 20 of 130. Sign in to see all of them.
Epidermolysis Bullosa Dystrophica (32) · Epidermolysis Bullosa (29) · Epidermolysis Bullosa Simplex (14) · Netherton Syndrome (11) · Dyskeratosis Congenita (9) · Pseudoxanthoma Elasticum (8) · Epidermolysis Bullosa, Junctional (7) · Anetoderma (6) · Ichthyosis (6) · Port-Wine Stain (5) · Retinal Diseases (5) · Anemia, Aplastic (4) · Bone Marrow Failure Disorders (4) · Fanconi Anemia (4)
Skin and Connective Tissue Diseases (128) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (126) · Skin Diseases (125) · Congenital Abnormalities (122) · Genetic Diseases, Inborn (114) · Skin Diseases, Genetic (110) · Skin Diseases, Vesiculobullous (61) · Connective Tissue Diseases (48) · Collagen Diseases (33) · Epidermolysis Bullosa (33) · Keratosis (29) · Infant, Newborn, Diseases (27) · Ichthyosis (23) · Abnormalities, Multiple (19)
fludarabine (7) · Gentamicins (6) · Whole-Body Irradiation (6) · fludarabine phosphate (6) · Alemtuzumab (5) · Cyclophosphamide (5) · Antilymphocyte Serum (4) · Mycophenolic Acid (4) · Tacrolimus (4) · Melphalan (3) · diacerein (3) · thymoglobulin (3) · Busulfan (2) · Cyclosporine (2) · Cyclosporins (2)
University of Southern California (5) · Centre Hospitalier Universitaire de Nice (4) · Gyroscope Therapeutics Limited (4) · Masonic Cancer Center, University of Minnesota (4) · Quoin Pharmaceuticals (4) · Mayo Clinic (3) · Northwestern University (3) · Phoenix Tissue Repair, Inc. (3) · Stanford University (3) · University Hospital, Toulouse (3) · Anterogen Co., Ltd. (2) · Boston Children's Hospital (2) · Castle Creek Pharmaceuticals, LLC (2) · Clinuvel Europe Limited (2) · Daiichi Sankyo (2)
United States (79) · France (26) · Germany (17) · United Kingdom (15) · Spain (12) · Australia (10) · Italy (8) · Austria (7) · Canada (6) · Israel (6) · Netherlands (5) · Sweden (5) · Poland (4) · Belgium (3) · Greece (3)
Jakub Tolar, MD, PhD (3) · David Woodley, MD (2) · Elena Pope, MD (2) · Jean Tang, MD, PhD (2) · Johann W. Bauer, MD (2) · Mary Spellman, MD (2) · Matt P Marinkovich, MD (2) · Michele De Luca, MD/Professor (2) · Tony Andrasfay (2) · Agnes Schwieger-Briel, MD (1) · Albert C Yan, MD (1) · Albert S Chiou, MD/MBA (1) · Alexandra DJ Mancini, MSc (1)
PMID 31541747, PMID 35234826, PMID 37314061, PMID 20083693, PMID 20383216, PMID 20691689, PMID 21704964, PMID 22517769, PMID 24102348, PMID 24952730, PMID 27015660, PMID 27802546, PMID 28691931, PMID 30843184, PMID 31215818, PMID 31578311, PMID 32634238, PMID 32750127, PMID 33011075, PMID 33159275, PMID 33214244, PMID 33491668, PMID 33750925, PMID 34086408, PMID 34665781, PMID 34857525, PMID 35218370, PMID 35347281, PMID 36253825, PMID 36868990, PMID 37170057, PMID 40268883, PMID 41224305, PMID 41637861, PMID 42164509, PMID 42193355
2017 (2), 2019 (2), UL1RR024150 (2), 1RC1DK086182 (1), 2008 (1), 2016 (1), 2023 (1), P30CA015704 (1), R01AR055914 (1), R01DK054681 (1), R01DK079866 (1)